RNA-based analysis of BRCA1 and BRCA2 gene alterations

被引:46
作者
Bonatti, Fabrizia
Pepe, Chiara
Tancredi, Mariella
Lombardi, Grazia
Aretini, Paolo
Sensi, Elisa
Falaschi, Elisabetta
Cipollini, Giovanna
Bevilacqua, Generoso
Caligo, Maria Adelaide
机构
[1] Univ Pisa, Sect Genet Oncol, Div Surg Mol & Ultrastruct Pathol, I-56100 Pisa, Italy
[2] Pisa Univ Hosp, Pisa, Italy
[3] MGM, Inst Mol Genet, Pisa, Italy
关键词
D O I
10.1016/j.cancergencyto.2006.05.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alterations in BRCA1 and BRCA2 genes account for a large proportion of hereditary breast and ovarian cancers. Mutations and variants of unknown pathological significance have been identified in both genes; however, most of them have been studied only at the genomic level, and their effect on mRNA expression remains unknown. We identified two BRCA1 and six BRCA2 splice site variants, and one BRCA2 alteration at exon 14. Our aim was to ascertain the effect on RNA processing of the variants still unclassified. We found that BRCA1 c.IVS11 + 1G > A, BRCA2 c.7252_7272delinsTG, BRCA2 c.IVS2 + IG > A, BRCA2 c.IVS 13-2A > G, BRCA2 c.IVS21 + 4A > G, and BRCA2 c.9345G > A lead to aberrant transcripts in lymphocytes. Five of these six splice site variants caused a complete inactivation of the mutant allele because they produced frameshift similar to previously described deleterious exonic variants. Therefore, we consider them to be true deleterious mutations, possibly associated with an increased lifetime risk of breast or ovarian cancer. BRCA1 c.IVS17 + 6C > G, BRCA2 c.IVS12-9del4, and BRCA2 IVS1-9del3 represent rare variants, not disrupting normal mRNA processing. The last two BRCA2 genetic variants had not been reported in the Breast Cancer Information Core BIC database. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:93 / 101
页数:9
相关论文
共 23 条
[1]   How did alternative splicing evolve? [J].
Ast, G .
NATURE REVIEWS GENETICS, 2004, 5 (10) :773-782
[2]   Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history [J].
Berry, DA ;
Parmigiani, G ;
Sanchez, J ;
Schildkraut, J ;
Winer, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :227-238
[3]  
Campos Berta, 2003, Hum Mutat, V22, P337, DOI 10.1002/humu.9176
[4]   Listening to silence and understanding nonsense: Exonic mutations that affect splicing [J].
Cartegni, L ;
Chew, SL ;
Krainer, AR .
NATURE REVIEWS GENETICS, 2002, 3 (04) :285-298
[5]   Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2 [J].
Claes, K ;
Poppe, B ;
Machackova, E ;
Coene, I ;
Foretova, L ;
De Paepe, A ;
Messiaen, L .
GENES CHROMOSOMES & CANCER, 2003, 37 (03) :314-320
[6]   Nomenclature for the description of human sequence variations [J].
den Dunnen, JT ;
Antonarakis, E .
HUMAN GENETICS, 2001, 109 (01) :121-124
[7]   A new alternative splice variant of BRCA1 containing an additional in-frame exon [J].
Fortin, J ;
Moisan, AM ;
Dumont, M ;
Leblanc, G ;
Labrie, Y ;
Durocher, F ;
Bessette, P ;
Bridge, P ;
Chiquette, J ;
Laframboise, R ;
Lépine, J ;
Lespérance, B ;
Pichette, R ;
Plante, M ;
Provencher, L ;
Voyer, P ;
Simard, J .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2005, 1731 (01) :57-65
[8]  
Hofmann W, 2003, J Med Genet, V40, pe23, DOI 10.1136/jmg.40.3.e23
[9]  
Hogervorst FBL, 2003, CANCER RES, V63, P1449
[10]   A Biochemical analysis demonstrates that the BRCA1 intronic variant IVS10-2A→C is a mutation [J].
Keaton, JC ;
Nielsen, DR ;
Hendrickson, BC ;
Pyne, MT ;
Scheuer, L ;
Ward, BE ;
Brothman, AR ;
Scholl, T .
JOURNAL OF HUMAN GENETICS, 2003, 48 (08) :399-403